Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

55.93
-2.3000-3.95%
Pre-market: 56.080.1500+0.27%04:01 EDT
Volume:4.14M
Turnover:233.91M
Market Cap:10.03B
PE:-32.46
High:57.95
Open:57.64
Low:54.50
Close:58.23
52wk High:104.32
52wk Low:41.73
Shares:179.40M
Float Shares:114.00M
Volume Ratio:0.92
T/O Rate:3.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7231
EPS(LYR):-1.4100
ROE:-81.58%
ROA:-9.07%
PB:24.10
PE(LYR):-39.67

Loading ...

Can Tempus AI’s (TEM) New ECG-AF Validation Deepen Its Edge in Clinical-Grade Healthcare AI?

Simply Wall St.
·
Jun 21

Movement Alert|Tempus AI Rises 6.11% in Regular Trading, FDA Approval of xT CDx Platform and Technical Rebound Lift Sentiment

Market Focus
·
Jun 15

Tempus AI says multi-center study validates FDA-cleared ECG model predicting 1-year atrial fibrillation risk

Reuters
·
Jun 11

Movement Alert|Tempus AI Intraday Rise 5.07% in Regular Trading, FDA Approval of xT CDx Platform Combined with Oversold Rebound Lifts Sentiment

Market Focus
·
Jun 10

Movement Alert|Tempus AI Falls 5.47% in Regular Trading, Major Shareholder Continued Selling Pressures Market Sentiment

Market Focus
·
Jun 10

Tempus unit Ambry study finds ExomeReveal RNA testing boosts clarity for uncertain exome results

Reuters
·
Jun 09

If AI Healthcare Wins Big These Three Stocks Could Matter

Simply Wall St.
·
Jun 08

Skip the Oura Ring IPO. Buy These 10 Stocks Instead.

InvestorPlace
·
Jun 07

Is Tempus AI’s (TEM) New Oncology Tools Quietly Redefining Its Precision Medicine Moat?

Simply Wall St.
·
Jun 06

Movement Alert|Tempus AI Intraday Decline 5.34%, Major Shareholder Persistent Selling and Sector Weakness Extend Selling Pressure

Market Focus
·
Jun 05

Movement Alert|Tempus AI Rises 5.28% in Regular Trading, FDA Approval of xT CDx Platform and New AI Launch Continue to Drive Momentum

Market Focus
·
Jun 04

Tempus AI director David R. Epstein reports disposal of 250 common shares worth $12,350

Reuters
·
Jun 04

Tempus AI launches open-source digital pathology consortium

TIPRANKS
·
Jun 03

Movement Alert|Tempus AI Intraday Decline 5.48%, Major Shareholder Continued Selling Pressure Compounded by Sector-Wide Weakness

Market Focus
·
Jun 03

Movement Alert|Tempus AI Falls 5.04% in Regular Trading, Trading at $50.6

Market Focus
·
Jun 02

Tempus AI assumed with a Peer Perform at Wolfe Research

TIPRANKS
·
Jun 02

Movement Alert|Tempus AI Rises 5.32% in Regular Trading, FDA Approves xT CDx Platform for Tumor-Only Genomic Profiling

Market Focus
·
Jun 01

Tempus AI announced the upcoming clinical availability of xH

TIPRANKS
·
Jun 01

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, Xh

THOMSON REUTERS
·
Jun 01

Guggenheim Reaffirms Their Buy Rating on Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jun 01